Adverse events in the nervous system associated with blinatumomab: a real-world study

Table 3 Univariate and multivariate analysis of fatal NST induced by blinatumomab

	Univariate		Multivariate
Variable	Waldχ²	P-value	β	S.E	Waldχ²	P-value	OR (95% CI)
Age	− 2.40 (t-test)	0.0167	− 0.00957	0.00439	4.7456	0.0294	0.99 (0.98–1.00)
Gender	2.84	0.0918	0.2554	0.1932	1.7481	0.1861	1.29 (0.88–1.89)
Dermatological medications	1.00	0.3181	0.4706	0.7779	0.3659	0.5453	1.60 (0.35–7.35)
Systemic corticosteroids, excluding sexual hormones and insulin	0.93	0.3354	0.00458	0.4749	0.0001	0.9923	1.00 (0.40–2.55)
Systemic anti-infective agents	1.00	0.3164	− 0.8313	0.3654	5.1754	0.0229	0.44 (0.21–0.89)
Antineoplastic and immunomodulating agents	0.67	0.4136	0.0700	0.2621	0.0712	0.7896	1.07 (0.64–1.79)
Musculoskeletal system medications	0.81	0.3669	0.3884	0.4010	0.9379	0.3328	1.47 (0.67–3.24)
Sensory organ system medications	0.74	0.3897	0.3141	0.7446	0.1779	0.6732	1.37 (0.32–5.89)
Antiparasitic, insecticidal, and anthelmintic drugs	0.19	0.6597	0.4839	0.5596	0.7475	0.3873	1.62 (0.54–4.86)
Genitourinary system and sexual hormones	0.01	0.9058	− 0.2863	0.3216	0.7928	0.3733	0.75 (0.40–1.41)
Nervous system medication	0.48	0.4888	0.2607	0.3126	0.6959	0.4042	1.30 (0.70–2.40)
			− 0.00002	0.5272	0.0000	1.0000	1.00 (0.36–2.81)
Digestive and metabolic system drugs	0.24	0.6224	− 0.4612	0.5268	0.7664	0.3813	0.63 (0.22–1.77)
Respiratory system medications	0.82	0.3659	− 0.00810	0.5032	0.0003	0.9872	0.99 (0.37–2.66)
Blood and hematopoietic organs medication	0.05	0.8239	− 0.2810	0.4676	0.3611	0.5479	0.76 (0.30–1.89)
Other miscellaneous drugs	1.70	0.1922	0.6322	0.4518	1.9579	0.1617	1.88 (0.78–4.56)

ISSN: 1741-7015